Stool tests may predict biologic success in ulcerative colitis within weeks

This study is testing whether two simple stool tests—fecal calprotectin and a fecal immunochemical test (FIT)—can predict early on if biologic therapy will help people with moderate-to-severe ulcerative colitis. Researchers will measure these markers at weeks 2 and 4 after starting treatment with vedolizumab or infliximab, then check if patients achieve remission by week 14 and healing of the gut lining by week 52. The goal is to find a non-invasive way to quickly tell if a treatment is working, potentially saving patients from months of ineffective therapy.